About Us
Rare Pediatric Pharmaceutical Company to address highly unmet orphan diseases primarily affecting young children around the world.
“Many infants around the world are suffering from rare forms of metabolic diseases without effective drugs. With more advanced gene detection and early childcare procedures, more number of these orphan diseases are being diagnosed and require immediate medical attention although no effective drugs are available.
Liberyx Therapeutics with its name origin, “Liber” meaning children in Latin and “Ryx” for drugs under Curyx platform, is focused on developing a number of drug compounds to treat rare diseases for the children with highly unmet medical needs, particularly in metabolic disorders.
Liberyx Therapeutics is dedicated to quickly bring patient-friendly, safe and efficacious drugs with both new chemical compounds and repurposed drugs for the infant and juvenile patients. With the support of Curyx platform, Liberyx Therapeutics is able to proceed with the regulatory pathways and clinical trials in a highly time-efficient and cost-effective manner.
Management Team
ALEX YANG J.D., L.L.M.
Chief Executive Officer
ANTHONY LAM CFA, CPA
Chief Financial Officer
HAHN-JUN LEE M.Sc., Ph.D.
Chief Science Officer
MARY SHATZOFF M.Sc.
Head of Regulatory Affairs
Colleen Johnson, M.S., D.A.B.T.
Luis A Rojas, Ph.D.
Head of Clinical Development
Science Advisory Board
KALIPADA PAHAN Ph.D.
THERON ODLAUG Ph.D.
JAY VIJAYAN Ph.D.
SCOTT BARABAN Ph.D.
Dr. Hynda K. Kleinman, Ph.D.
Dr. David R. Luke, BSc.Pharm
